Nuvelo(NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo(NUVO)

NUVO 0.170

+169,917.0%

Aug 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (104)	10/25/2006 9:25:01 AM
From: Arthur Radley	Read Replies (2) of 140

At least one potential competitor has run into problems... CHICAGO, Oct 25 (Reuters) - An experimental stroke treatment designed to copy a protein found in vampire bat saliva has been put on hold because of potential safety problems, its developers said on Wednesday. Forest Laboratories Inc.(FRX.N: Quote, Profile, Research) and its German development partner Paion AG (PA8G.DE: Quote, Profile, Research) said they decided to stop enrolling patients in a late-stage study of the compound desmoteplase as a treatment for stroke until further data have been analyzed. An independent Data Monitoring Committee has requested additional data in order to evaluate a potential safety signal. Desmoteplase is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat Desmodus rotundus.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next